Overview of Cellular Immunotherapy for Patients with Glioblastoma
High grade gliomas (HGG) including glioblastomas (GBM) are the most common and devastating primary brain tumours. Despite important progresses in GBM treatment that currently includes surgery combined to radio- and chemotherapy, GBM patients' prognosis remains very poor. Immunotherapy is one of...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2010/689171 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849308337098719232 |
|---|---|
| author | Elodie Vauleon Tony Avril Brigitte Collet Jean Mosser Véronique Quillien |
| author_facet | Elodie Vauleon Tony Avril Brigitte Collet Jean Mosser Véronique Quillien |
| author_sort | Elodie Vauleon |
| collection | DOAJ |
| description | High grade gliomas (HGG) including glioblastomas (GBM) are the most common and devastating primary brain tumours. Despite important progresses in GBM treatment that currently includes surgery combined to radio- and chemotherapy, GBM patients' prognosis remains very poor. Immunotherapy is one of the new promising therapeutic approaches that can specifically target tumour cells. Such an approach could also maintain long term antitumour responses without inducing neurologic defects. Since the past 25 years, adoptive and active immunotherapies using lymphokine-activated killer cells, cytotoxic T cells, tumour-infiltrating lymphocytes, autologous tumour cells, and dendritic cells have been tested in phase I/II clinical trials with HGG patients. This paper inventories these cellular immunotherapeutic strategies and discusses their efficacy, limits, and future perspectives for optimizing the treatment to achieve clinical benefits for GBM patients. |
| format | Article |
| id | doaj-art-0e255c1042be45988da8c0e70f47df2d |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-0e255c1042be45988da8c0e70f47df2d2025-08-20T03:54:29ZengWileyClinical and Developmental Immunology1740-25221740-25302010-01-01201010.1155/2010/689171689171Overview of Cellular Immunotherapy for Patients with GlioblastomaElodie Vauleon0Tony Avril1Brigitte Collet2Jean Mosser3Véronique Quillien4Département de Biologie, Centre Eugène Marquis, Rue de la bataille Flandres Dunkerque, CS44229, 35042 Rennes cedex, FranceDépartement de Biologie, Centre Eugène Marquis, Rue de la bataille Flandres Dunkerque, CS44229, 35042 Rennes cedex, FranceDépartement de Biologie, Centre Eugène Marquis, Rue de la bataille Flandres Dunkerque, CS44229, 35042 Rennes cedex, FranceUMR6061 CNRS, Université de Rennes 1, IFR 140, CS34317, 35043 Rennes cedex, FranceDépartement de Biologie, Centre Eugène Marquis, Rue de la bataille Flandres Dunkerque, CS44229, 35042 Rennes cedex, FranceHigh grade gliomas (HGG) including glioblastomas (GBM) are the most common and devastating primary brain tumours. Despite important progresses in GBM treatment that currently includes surgery combined to radio- and chemotherapy, GBM patients' prognosis remains very poor. Immunotherapy is one of the new promising therapeutic approaches that can specifically target tumour cells. Such an approach could also maintain long term antitumour responses without inducing neurologic defects. Since the past 25 years, adoptive and active immunotherapies using lymphokine-activated killer cells, cytotoxic T cells, tumour-infiltrating lymphocytes, autologous tumour cells, and dendritic cells have been tested in phase I/II clinical trials with HGG patients. This paper inventories these cellular immunotherapeutic strategies and discusses their efficacy, limits, and future perspectives for optimizing the treatment to achieve clinical benefits for GBM patients.http://dx.doi.org/10.1155/2010/689171 |
| spellingShingle | Elodie Vauleon Tony Avril Brigitte Collet Jean Mosser Véronique Quillien Overview of Cellular Immunotherapy for Patients with Glioblastoma Clinical and Developmental Immunology |
| title | Overview of Cellular Immunotherapy for Patients with Glioblastoma |
| title_full | Overview of Cellular Immunotherapy for Patients with Glioblastoma |
| title_fullStr | Overview of Cellular Immunotherapy for Patients with Glioblastoma |
| title_full_unstemmed | Overview of Cellular Immunotherapy for Patients with Glioblastoma |
| title_short | Overview of Cellular Immunotherapy for Patients with Glioblastoma |
| title_sort | overview of cellular immunotherapy for patients with glioblastoma |
| url | http://dx.doi.org/10.1155/2010/689171 |
| work_keys_str_mv | AT elodievauleon overviewofcellularimmunotherapyforpatientswithglioblastoma AT tonyavril overviewofcellularimmunotherapyforpatientswithglioblastoma AT brigittecollet overviewofcellularimmunotherapyforpatientswithglioblastoma AT jeanmosser overviewofcellularimmunotherapyforpatientswithglioblastoma AT veroniquequillien overviewofcellularimmunotherapyforpatientswithglioblastoma |